Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Profit After Tax (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Profit After Tax for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax fell 6.68% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.1 million, a 161.85% increase, with the full-year FY2024 number at -$7.2 million, down 17.33% from a year prior.
  • Profit After Tax was -$1.3 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $7.7 million in Q1 2025 to a low of -$8.2 million in Q4 2022.
  • A 5-year average of -$1.3 million and a median of -$1.6 million in 2024 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 5093.67% in 2022, then soared 338.64% in 2025.
  • NovaBay Pharmaceuticals' Profit After Tax stood at -$158000.0 in 2021, then plummeted by 5093.67% to -$8.2 million in 2022, then surged by 92.53% to -$613000.0 in 2023, then skyrocketed by 41.6% to -$358000.0 in 2024, then plummeted by 261.17% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Profit After Tax are -$1.3 million (Q3 2025), -$1.9 million (Q2 2025), and $7.7 million (Q1 2025).